Paul W. Wales

Paul W. Wales

Auto-generated profile, based on publicly available information

Paul W. Wales

Division of Pediatric Surgery, Department of Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Early Human Development
Verified
Journal Article
Closed access
SSStephanie So
Stephanie So
CPCatherine Patterson
Catherine Patterson
AGAnna Gold
Anna Gold
ARAlaine Rogers
Alaine Rogers
CBChristina Belza
Christina Belza
PWPaul W. Wales
Paul W. Wales

30 April 2022 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
MPMirielle Pauline
Mirielle Pauline
JFJanelle Fouhse
Janelle Fouhse
THTierah Hinchliffe
Tierah Hinchliffe
PWPamela Wizzard
Pamela Wizzard
PNPatrick Nation
Patrick Nation
JTJustine Turner
Justine Turner

2 June 2022 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CBChristina Belza
Christina Belza
WUWendy J. Ungar
Wendy J. Ungar
YAYaron Avitzur
Yaron Avitzur
RSRobyn Stremler
Robyn Stremler
DFDarcy Fehlings
Darcy Fehlings
PWPaul W. Wales
Paul W. Wales

21 December 2022 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
CBChristina Belza
Christina Belza
YAYaron Avitzur
Yaron Avitzur
WUWendy J. Ungar
Wendy J. Ungar
RSRobyn Stremler
Robyn Stremler
DFDarcy Fehlings
Darcy Fehlings
PWPaul W. Wales
Paul W. Wales

14 July 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
ARAmin J. Roberts
Amin J. Roberts
PWPaul W. Wales
Paul W. Wales
SBSue V. Beath
Sue V. Beath
HEHelen M. Evans
Helen M. Evans
JHJonathan Hind
Jonathan Hind
YAYaron Avitzur
Yaron Avitzur
Deciding which patients would benefit from intestinal transplantation (IT) remains an ethical/clinical dilemma. New criteria* were proposed in 2015: ≥2 intensive care unit (ICU) admissions, loss of ≥3 central venous catheter (CVC) sites, and persistently elevated conjugated bilirubin (CB ≥ 75 μmol/L) despite 6 weeks of lipid modification strategies. We performed a retrospective, international, multicenter validation study of 443 children (61% male, median gestational age 34 weeks [IQR 29-37]), diagnosed with IF between 2010 and 2015. Primary outcome measure was death or IT. Sensitivity, specificity, NPV, PPV, and probability of death/transplant (OR, 95% confidence intervals) were calculated for each criterion. Median age at IF diagnosis was 0.1 years (IQR 0.03-0.14) with median follow-up of 3.8 years (IQR 2.3-5.3). Forty of 443 (9%) patients died, 53 of 443 (12%) were transplanted; 11 died posttransplant. The validated criteria had a high predictive value of death/IT; ≥2 ICU admissions (p < .0001, OR 10.2, 95% CI 4.0-25.6), persistent CB ≥ 75 μmol/L (p < .0001, OR 8.2, 95% CI 4.8-13.9). and loss of ≥3 CVC sites (p = .0003, OR 5.7, 95% CI 2.2-14.7). This large, multicenter, international study in a contemporary cohort confirms the validity of the Toronto criteria. These validated criteria should guide listing decisions in pediatric IT.

14 June 2024 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
PWPaul W. Wales
Paul W. Wales
SHSusan Hill
Susan Hill
IRIan Robinson
Ian Robinson
BRBram P. Raphael
Bram P. Raphael
CMCheney Matthews
Cheney Matthews
SKSamuel Kocoshis
Samuel Kocoshis
Objectives: Patients with short bowel syndrome‐associated intestinal failure (SBS‐IF) require long‐term parenteral nutrition and/or intravenous fluids (PN/IV) to maintain fluid or nutritional balance. We report the long‐term safety, efficacy, and predictors of response in pediatric patients with SBS‐IF receiving teduglutide over 96 weeks.Methods: This was a pooled, post hoc analysis of two open‐label, long‐term extension (LTE) studies (NCT02949362 and NCT02954458) in children with SBS‐IF. Endpoints included treatment‐emergent adverse events (TEAEs) and clinical response (≥20% reduction in PN/IV volume from baseline). A multivariable linear regression identified predictors of teduglutide response; the dependent variable was mean change in PN/IV volume at each visit over 96 weeks.Results: Overall, 85 patients were analyzed; 78 patients received teduglutide in the parent and/or LTE studies (any teduglutide [TED] group), while seven patients did not receive teduglutide in either the parent or LTE studies. Most TEAEs were moderate or severe in intensity in both groups. By week 96, 82.1% of patients from the any TED group achieved a clinical response, with a mean fluid decrease of 30.1 mL/kg/day and an energy decrease of 21.6 kcal/kg/day. Colon‐in‐continuity, non‐White race, older age at baseline, longer duration of teduglutide exposure, and increasing length of remaining small intestine were significantly associated with a reduction in mean PN/IV volume requirements.Conclusions: In pediatric patients with SBS‐IF, teduglutide treatment resulted in long‐term reductions in PN/IV requirements. The degree of PN/IV volume reduction depended on the duration of teduglutide exposure, underlying bowel anatomy, and demographics.